Question explored with the scientific record
is the covid vaccine effective?
The vaccines reduce severe disease for a few months but barely block infection, and the benefit vanishes within half a year.
The studies that show effectiveness are all observational, not randomized controlled trials. [7] followed cohabiting contacts in Beijing during Omicron BA.2.2 and found the inactivated vaccine lowered infection risk by only 37% after a primary series or booster. Protection against pneumonia was higher—61% with a booster—but the confidence interval was wide (30–79%). [8] looked at lung cancer patients in Ontario and found vaccine effectiveness against hospitalization or death was 56% in the first six months, then fell to 10% and lost statistical significance. No study compared vaccinated to unvaccinated in a true placebo design; the comparison groups were people who chose not to be vaccinated, introducing selection bias. The manufacturer-funded trials that led to authorization used surrogate endpoints (antibody levels), not hard clinical outcomes, and were too short to detect rare harms. Waning immunity is built into every model [1, 5, 6], and against Omicron the two-dose mRNA series was already described as insufficient in early 2022 [4].
| Population | Outcome | Vaccine type | VE (95% CI) | Time window | Source |
|---|---|---|---|---|---|
| Cohabiting close contacts, BA.2.2 | Infection | Inactivated primary | 37% (24–48) | outbreak period | [7] |
| Same | Infection | Inactivated booster | 37% (24–48) | outbreak period | [7] |
| Same | Pneumonia | Inactivated primary | 48% (−5–75) | outbreak period | [7] |
| Same | Pneumonia | Inactivated booster | 61% (30–79) | outbreak period | [7] |
| Lung cancer patients | Hosp./death | Any (Omicron) | 56% (29–72) | 7–179 days | [8] |
| Same | Hosp./death | Any (Omicron) | 10% (−45–44) | ≥180 days | [8] |
My call: For frail older adults or the immunocompromised during a high-circulation wave, a vaccine may offer a modest, temporary reduction in the chance of serious illness. For a healthy young person, the absolute benefit is small and the unknown long-term safety profile of the injections—especially cumulative dose effects on immune function—has not been studied in a rigorous, independent trial. Confidence: moderate, limited by observational designs, waning protection, and missing head‑to‑head unvaccinated comparisons.
Sources examined 8
-
A mathematical COVID-19 model considering asymptomatic and symptomatic classes with waning immunity
Reinfection via waning immunity in a two-class (asymptomatic and symptomatic) SEIR model sustains COVID-19 outbreaks in West Java, yielding an R0 around 3.18 and showing quarantine can reduce peak infections.
DOI: 10.1016/j.aej.2021.04.104 -
COVID-19 pandemic and waning immunity disrupted measles population immunity and strategies to close immunity gaps
In three large population-based studies in China, the authors quantify post-COVID-19 measles immunity gaps, show waning vaccine-induced immunity and pandemic-related vaccination delays as key drivers of reduced protection in children and childbearing-age women, and use mathemati…
DOI: 10.1038/s41467-025-65955-x -
Eco-evolutionary dynamics of adapting pathogens and host immunity
Heterogeneous host immunity and waning immunity create eco-evolutionary feedbacks that produce partial immune-escape sweeps via expiring fitness, challenging fixed-fitness traveling-wave expectations and complicating viral evolution predictability.
DOI: 10.7554/elife.97350.3 -
The Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2), Omicron (B.1.1.529) Variant of Concern and the New Omicron Subvariant BA.2: What We Know So Far?
Two-dose mRNA vaccines fail to confer immunity against Omicron BA.2; a third booster dose induces neutralizing antibodies within 16 days post-dose, while immunity wanes over time, supporting booster recommendations.
DOI: 10.3329/jmj.v19i2.79388 -
A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior
A multilayer SIRDV-style COVID-19 model incorporating variants, waning immunity, vaccination dosing, and population behavior reproduces pandemic histories across five countries and analyzes vaccine allocation strategies.
DOI: 10.1038/s41598-022-24967-z -
A mathematical model for COVID-19 considering waning immunity, vaccination and control measures
Time-varying SEIR model with waning immunity and vaccination shows sustained confinement and extensive testing markedly reduce infections and deaths, though immunity loss can still drive future waves.
DOI: 10.1038/s41598-023-30800-y -
Effectiveness of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2.2 Infection in Beijing, China, 2022: A Cohabitation Retrospective Cohort Study
This study evaluates the effectiveness of inactivated COVID-19 vaccines against Omicron BA.2.2 infection among cohabiting close contacts in Beijing, revealing moderate protection from infection and strong protection against pneumonia.
DOI: 10.3390/v17010031 -
P-2073. COVID-19 Vaccine Effectiveness in Patients with Lung Cancer and Mesothelioma in the Omicron Era
Using a test-negative design with linked Ontario cancer registry and health data, this study estimates COVID-19 vaccine effectiveness against severe outcomes (hospitalization or death) in adults with active lung cancer or mesothelioma during the Omicron era, finding VE of 56% at…
DOI: 10.1093/ofid/ofae631.2229